The story has been updated to include comments from the company's earnings conference call.

NEW YORK (GenomeWeb News) – CombiMatrix today said that revenues in the fourth quarter rose 25 percent year over year as revenues from core prenatal testing markets spiked 161 percent.

For the three months ended December 31, 2012, the Irvine, Calif.-based firm saw revenues increase to $1.5 million from $1.2 million a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.